Phase I study of single-dose BMY-28100, a new oral cephalosporin.

The objective of this Phase I study was to evaluate the safety, tolerance, and pharmacokinetics of BMY-28100 in 36 male subjects after the administration of single oral doses of 250, 500, and 1,000 mg. The subjects were divided into groups of 12 per dose group. All subjects completed the study, and...

ver descrição completa

Detalhes bibliográficos

Publicado no:	Antimicrob Agents Chemother
Principais autores:	Barbhaiya, R H, Gleason, C R, Shyu, W C, Wilber, R B, Martin, R R, Pittman, K A
Formato:	Artigo
Idioma:	Inglês
Publicado em:	American Society for Microbiology (ASM) 1990
Assuntos:	Research Article
Acesso em linha:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC171556/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/2327766/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.34.2.202
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!